Marker Therapeutics, Inc.

Monthly Archives: March 2016

TapImmune to Present at 28th Annual ROTH Conference on March 16, 2016

TapImmune-Corporate-Presentation-2016 JACKSONVILLE, FLORIDA, March 14, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment of cancer, including metastatic cancer, announced today the company’s Director, Dr.
Read More